MedTrace Logo

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

NCT03969888 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2023-06-28

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.

Conditions

Interventions

DRUG

ABBV-3067

Tablet taken orally.

DRUG

Placebo ABBV-3067

Tablet taken orally.

DRUG

ABBV-2222

Capsule taken orally.

DRUG

Placebo ABBV-2222

Capsule taken orally.

Sponsors & Collaborators

Principal Investigators

  • ABBVIE INC. · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-11
Primary Completion
2022-06-09
Completion
2022-06-09
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Canada
  • Czechia
  • France
  • Hungary
  • Netherlands
  • New Zealand
  • Poland
  • Serbia
  • Slovakia
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03969888 on ClinicalTrials.gov